All In Biotech

Drug Trial Radar · NCT00314951

Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12h With 125 mg Vancomycin Taken q6h for Ten Days in Subjects With Clostridium Difficile-Associated Diarrhea

Last checked: Nov 19, 2026Latest source record: Apr 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 629 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

629

Actual

Start

May 2, 2006

Primary completion

Jul 23, 2008

Study completion Aug 21, 2008

Sponsor

Sponsor type
Industry
First posted
Apr 17, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a comparative study to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).

Conditions

  • Clostridium Infections
  • Diarrhea

Interventions

  • FidaxomicinDrug

    200 mg oral capsules two times daily (q12h regimen)

  • VancomycinDrug

    125 mg capsules q6hr (4 times a day)

  • Matching Placebo to FidaxomicinDrug

    Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cure Rate at End of TherapyTime frame: Study day 10 (+/- 2 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.